Hypertension: Renal Denervation: Hype After Initial Hope/Lessons to be Learned From its Fall/Other Methods Influencing the Autonomic Nervous System

Authors

  • Costas Tsioufis First Department of Cardiology, University of Athens, Hippokration Hospital, Athens, Greece
  • Kyriakos Dimitriadis First Department of Cardiology, University of Athens, Hippokration Hospital, Athens, Greece
  • Christodoulos Stefanadis First Department of Cardiology, University of Athens, Hippokration Hospital, Athens, Greece

DOI:

https://doi.org/10.2015/hc.v9i1%20Sup.658

Keywords:

renal sympathetic denervation, resistant hypertension, sympathetic nervous system

Abstract

The unexpected announcement of Symplicity HTN-3 trial by the sponsor company that renal sympathetic denervation (RDN) failed to meet its primary efficacy end-point at 6 months raised concerns regarding the extent of blood pressure (BP) lowering results of the procedure.1 But the answer to the “burning†question of whether we should stop research and clinical implementation of RDN based on the results of one trial needs a cautious approach.

Downloads

Published

2014-05-30

Issue

Section

ATHENS CARDIOLOGY UPDATE 2014